<p>在過去三個月中，9 位分析師對 Hinge Health（紐約證券交易所代碼：HNGE）進行了評估，提供了從看漲到看跌的多樣化意見。</p>
<p>下表提供了他們最近評級的快照，展示了過去 30 天情緒的演變，並與前幾個月進行了比較。</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看漲</strong></th>
<th align="right"><strong>稍微看漲</strong></th>
<th align="right"><strong>無所謂</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>總評級</strong></td>
<td align="right">3</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>過去 30 天</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 個月前</strong></td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 個月前</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 個月前</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>在對 12 個月價格目標的評估中，分析師為 Hinge Health 揭示了見解，呈現出平均目標為 64.11 美元，最高估計為 71.00 美元，最低估計為 59.00 美元。當前平均價格目標較之前的 65.71 美元下降了 2.43%。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1769176819_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="價格目標圖表" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1769176819_0.png"/></p>
<h2>解讀分析師評級：深入分析</h2>
<p>通過最近的分析師行動，分析 Hinge Health 在金融專家眼中的認知。以下摘要呈現了關鍵分析師、他們的最新評估以及對評級和價格目標的調整。</p>
<table>
<thead>
<tr>
<th>分析師</th>
<th>分析師公司</th>
<th>採取的行動</th>
<th>評級</th>
<th>當前價格目標</th>
<th>之前價格目標</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gene Mannheimer</td>
<td>Freedom Capital Markets</td>
<td>宣佈</td>
<td>買入</td>
<td>59.00 美元</td>
<td>-</td>
</tr>
<tr>
<td>Jessica Tassan</td>
<td>Piper Sandler</td>
<td>下調</td>
<td>超配</td>
<td>60.00 美元</td>
<td>71.00 美元</td>
</tr>
<tr>
<td>Stan Berenshteyn</td>
<td>Wells Fargo</td>
<td>宣佈</td>
<td>超配</td>
<td>68.00 美元</td>
<td>-</td>
</tr>
<tr>
<td>Scott Schoenhaus</td>
<td>Keybanc</td>
<td>下調</td>
<td>超配</td>
<td>70.00 美元</td>
<td>72.00 美元</td>
</tr>
<tr>
<td>Ryan MacDonald</td>
<td>Needham</td>
<td>維持</td>
<td>買入</td>
<td>59.00 美元</td>
<td>59.00 美元</td>
</tr>
<tr>
<td>Saket Kalia</td>
<td>Barclays</td>
<td>下調</td>
<td>超配</td>
<td>60.00 美元</td>
<td>65.00 美元</td>
</tr>
<tr>
<td>Richard Close</td>
<td>Canaccord Genuity</td>
<td>上調</td>
<td>買入</td>
<td>65.00 美元</td>
<td>61.00 美元</td>
</tr>
<tr>
<td>Saket Kalia</td>
<td>Barclays</td>
<td>上調</td>
<td>超配</td>
<td>65.00 美元</td>
<td>62.00 美元</td>
</tr>
<tr>
<td>Jessica Tassan</td>
<td>Piper Sandler</td>
<td>上調</td>
<td>超配</td>
<td>71.00 美元</td>
<td>70.00 美元</td>
</tr>
</tbody>
</table>
<h3>關鍵見解：</h3>
<ul>
<li><strong>採取的行動：</strong> 針對動態市場條件和公司表現，分析師更新他們的建議。無論是 ‘維持’，‘上調’ 還是 ‘下調’ 他們的立場，都表明他們對 Hinge Health 近期發展的反應。這一見解提供了分析師對公司當前狀態的看法快照。</li>
<li><strong>評級：</strong> 提供全面視角，分析師對股票進行定性評估，從 ‘跑贏大盤’ 到 ‘跑輸大盤’。這些評級傳達了對 Hinge Health 相對於更廣泛市場表現的預期。</li>
<li><strong>價格目標：</strong> 分析師提供價格目標的見解，給出 Hinge Health 股票未來價值的估計。這一比較揭示了分析師預期隨時間變化的趨勢。</li>
</ul>
<p>將這些分析師評估與相關財務指標進行分析，可以提供 Hinge Health 市場地位的全面視角。保持信息靈通，並在我們的評級表的幫助下做出數據驅動的決策。</p>
<p>隨時瞭解 Hinge Health 分析師評級。</p>
<h2>關於 Hinge Health</h2>
<p>Hinge Health Inc 是一個技術平台，旨在幫助個人治療和預防關節和肌肉疼痛。通過結合人工智能驅動的運動跟蹤技術，該公司的平台幫助會員解決肌肉骨骼（MSK）問題，提高會員的治療效果，並支持客户的成本降低。該公司的客户是自保僱主。</p>
<h3>Hinge Health 的經濟影響：分析</h3>
<p><strong>市值：</strong> 相較於行業平均水平，公司市值較小，面臨獨特挑戰。</p>
<p><strong>收入增長：</strong> 在過去 3 個月中，Hinge Health 表現積極，截至 2025 年 9 月 30 日，收入增長率為 <strong>53.27%</strong>。這反映了公司營業收入的顯著增加。與醫療保健行業的其他公司相比，該公司的增長率高於同行平均水平。</p>
<p><strong>淨利潤率：</strong> Hinge Health 的淨利潤率低於行業平均水平，表明在維持強勁盈利能力方面面臨挑戰。淨利潤率為 <strong>-1.2%</strong>，公司可能在有效成本管理方面遇到困難。</p>
<p><strong>股本回報率（ROE）：</strong> Hinge Health 的 ROE 低於行業標準，表明在有效利用股本方面存在困難。ROE 為 <strong>-0.97%</strong>，公司可能在為股東提供滿意回報方面面臨挑戰。</p>
<p><strong>資產回報率（ROA）：</strong> Hinge Health 的 ROA 低於行業標準，表明在有效利用資產方面存在困難。ROA 為 <strong>-0.25%</strong>，公司可能在從其資產中提供滿意回報方面面臨挑戰。</p>
<p><strong>債務管理：</strong> Hinge Health 的債務與股本比率低於行業規範，表明其財務結構良好，比例為 <strong>0.04</strong>。</p>
<h2>什麼是分析師評級？</h2>
<p>分析師是銀行和金融系統中的專家，通常為特定股票或特定行業報告。這些人研究公司財務報表，參加電話會議和會議，並與相關內部人士交談，以確定股票的分析師評級。通常，分析師每季度會對每隻股票進行評級。</p>
<p>除了他們的評估外，一些分析師還通過提供關鍵指標的預測（如收益、收入和增長估計）來擴展他們的見解。這些補充信息為交易者提供了進一步的指導。必須認識到，儘管他們是專家，分析師也是人，只能根據他們的信念提供預測。</p>
<p>本文由 Benzinga 的自動內容引擎生成，並由編輯審核。</p>

標普醫療保健服務 ETF - SPDR

美國醫藥設備 ETF - iShares

HNGE

標普健康醫療設備 ETF - SPDR

美國醫療保健供應商 ETF - iShares

<p>分析師在過去三個月對 Hinge Health (NYSE:HNGE) 進行了評估，顯示出看漲和看跌情緒的混合。12 個月的平均目標價格為 64.11 美元，較之前的 65.71 美元有所下降。最近的行動包括來自不同分析師的評級上調和下調，反映了市場狀況。Hinge Health 的收入增長率為 53.27%，但面臨淨利潤率為 -1.2% 的挑戰，以及較低的股本回報率和資產回報率。公司的債務與股本比率為 0.04，表明其財務結構良好</p>

<p>Throughout the last three months, 9 analysts have evaluated Hinge Health (NYSE: HNGE), offering a diverse set of opinions from bullish to bearish.</p>
<div class="lb-trans"><p>在過去三個月中，9 位分析師對 Hinge Health（紐約證券交易所代碼：HNGE）進行了評估，提供了從看漲到看跌的多樣化意見。</p>
</div><p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<div class="lb-trans"><p>下表提供了他們最近評級的快照，展示了過去 30 天情緒的演變，並與前幾個月進行了比較。</p>
</div><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看漲</strong></th>
<th align="right"><strong>稍微看漲</strong></th>
<th align="right"><strong>無所謂</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>總評級</strong></td>
<td align="right">3</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>過去 30 天</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 個月前</strong></td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 個月前</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 個月前</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
</div><p>In the assessment of 12-month price targets, analysts unveil insights for Hinge Health, presenting an average target of $64.11, a high estimate of $71.00, and a low estimate of $59.00. A 2.43% drop is evident in the current average compared to the previous average price target of $65.71.</p>
<div class="lb-trans"><p>在對 12 個月價格目標的評估中，分析師為 Hinge Health 揭示了見解，呈現出平均目標為 64.11 美元，最高估計為 71.00 美元，最低估計為 59.00 美元。當前平均價格目標較之前的 65.71 美元下降了 2.43%。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1769176819_0.png" alt="price target chart" original-src="https://www.benzinga.com/files/images/story/2026/1769176819_0.png"/></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<div class="lb-trans"><h2>解讀分析師評級：深入分析</h2>
</div><p>The perception of Hinge Health by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<div class="lb-trans"><p>通過最近的分析師行動，分析 Hinge Health 在金融專家眼中的認知。以下摘要呈現了關鍵分析師、他們的最新評估以及對評級和價格目標的調整。</p>
</div><table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gene Mannheimer</td>
<td>Freedom Capital Markets</td>
<td>Announces</td>
<td>Buy</td>
<td>$59.00</td>
<td>-</td>
</tr>
<tr>
<td>Jessica Tassan</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$60.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>Stan Berenshteyn</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Overweight</td>
<td>$68.00</td>
<td>-</td>
</tr>
<tr>
<td>Scott Schoenhaus</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$70.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Ryan MacDonald</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$59.00</td>
<td>$59.00</td>
</tr>
<tr>
<td>Saket Kalia</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$60.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Richard Close</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$65.00</td>
<td>$61.00</td>
</tr>
<tr>
<td>Saket Kalia</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$65.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Jessica Tassan</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$71.00</td>
<td>$70.00</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>分析師</th>
<th>分析師公司</th>
<th>採取的行動</th>
<th>評級</th>
<th>當前價格目標</th>
<th>之前價格目標</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gene Mannheimer</td>
<td>Freedom Capital Markets</td>
<td>宣佈</td>
<td>買入</td>
<td>59.00 美元</td>
<td>-</td>
</tr>
<tr>
<td>Jessica Tassan</td>
<td>Piper Sandler</td>
<td>下調</td>
<td>超配</td>
<td>60.00 美元</td>
<td>71.00 美元</td>
</tr>
<tr>
<td>Stan Berenshteyn</td>
<td>Wells Fargo</td>
<td>宣佈</td>
<td>超配</td>
<td>68.00 美元</td>
<td>-</td>
</tr>
<tr>
<td>Scott Schoenhaus</td>
<td>Keybanc</td>
<td>下調</td>
<td>超配</td>
<td>70.00 美元</td>
<td>72.00 美元</td>
</tr>
<tr>
<td>Ryan MacDonald</td>
<td>Needham</td>
<td>維持</td>
<td>買入</td>
<td>59.00 美元</td>
<td>59.00 美元</td>
</tr>
<tr>
<td>Saket Kalia</td>
<td>Barclays</td>
<td>下調</td>
<td>超配</td>
<td>60.00 美元</td>
<td>65.00 美元</td>
</tr>
<tr>
<td>Richard Close</td>
<td>Canaccord Genuity</td>
<td>上調</td>
<td>買入</td>
<td>65.00 美元</td>
<td>61.00 美元</td>
</tr>
<tr>
<td>Saket Kalia</td>
<td>Barclays</td>
<td>上調</td>
<td>超配</td>
<td>65.00 美元</td>
<td>62.00 美元</td>
</tr>
<tr>
<td>Jessica Tassan</td>
<td>Piper Sandler</td>
<td>上調</td>
<td>超配</td>
<td>71.00 美元</td>
<td>70.00 美元</td>
</tr>
</tbody>
</table>
</div><h3>Key Insights:</h3>
<div class="lb-trans"><h3>關鍵見解：</h3>
</div><ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Hinge Health. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Hinge Health compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Hinge Health's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>採取的行動：</strong> 針對動態市場條件和公司表現，分析師更新他們的建議。無論是 ‘維持’，‘上調’ 還是 ‘下調’ 他們的立場，都表明他們對 Hinge Health 近期發展的反應。這一見解提供了分析師對公司當前狀態的看法快照。</li>
<li><strong>評級：</strong> 提供全面視角，分析師對股票進行定性評估，從 ‘跑贏大盤’ 到 ‘跑輸大盤’。這些評級傳達了對 Hinge Health 相對於更廣泛市場表現的預期。</li>
<li><strong>價格目標：</strong> 分析師提供價格目標的見解，給出 Hinge Health 股票未來價值的估計。這一比較揭示了分析師預期隨時間變化的趨勢。</li>
</ul>
</div><p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Hinge Health's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<div class="lb-trans"><p>將這些分析師評估與相關財務指標進行分析，可以提供 Hinge Health 市場地位的全面視角。保持信息靈通，並在我們的評級表的幫助下做出數據驅動的決策。</p>
</div><p>Stay up to date on Hinge Health analyst ratings.</p>
<div class="lb-trans"><p>隨時瞭解 Hinge Health 分析師評級。</p>
</div><h2>About Hinge Health</h2>
<div class="lb-trans"><h2>關於 Hinge Health</h2>
</div><p>Hinge Health Inc is a technology platform for individuals seeking to treat and prevent joint and muscle pain. Through a combination of AI-powered motion tracking technology, the Company's platform helps members address musculoskeletal (MSK) conditions, enables improved member outcomes and supports cost reductions for its clients. The Company's clients are self-insured employers.</p>
<div class="lb-trans"><p>Hinge Health Inc 是一個技術平台，旨在幫助個人治療和預防關節和肌肉疼痛。通過結合人工智能驅動的運動跟蹤技術，該公司的平台幫助會員解決肌肉骨骼（MSK）問題，提高會員的治療效果，並支持客户的成本降低。該公司的客户是自保僱主。</p>
</div><h3>Hinge Health's Economic Impact: An Analysis</h3>
<div class="lb-trans"><h3>Hinge Health 的經濟影響：分析</h3>
</div><p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<div class="lb-trans"><p><strong>市值：</strong> 相較於行業平均水平，公司市值較小，面臨獨特挑戰。</p>
</div><p><strong>Revenue Growth:</strong> Over the 3M period, Hinge Health showcased positive performance, achieving a revenue growth rate of <strong>53.27%</strong> as of 30 September, 2025. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.</p>
<div class="lb-trans"><p><strong>收入增長：</strong> 在過去 3 個月中，Hinge Health 表現積極，截至 2025 年 9 月 30 日，收入增長率為 <strong>53.27%</strong>。這反映了公司營業收入的顯著增加。與醫療保健行業的其他公司相比，該公司的增長率高於同行平均水平。</p>
</div><p><strong>Net Margin:</strong> Hinge Health's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>-1.2%,</strong> the company may face hurdles in effective cost management.</p>
<div class="lb-trans"><p><strong>淨利潤率：</strong> Hinge Health 的淨利潤率低於行業平均水平，表明在維持強勁盈利能力方面面臨挑戰。淨利潤率為 <strong>-1.2%</strong>，公司可能在有效成本管理方面遇到困難。</p>
</div><p><strong>Return on Equity (ROE):</strong> Hinge Health's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>-0.97%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<div class="lb-trans"><p><strong>股本回報率（ROE）：</strong> Hinge Health 的 ROE 低於行業標準，表明在有效利用股本方面存在困難。ROE 為 <strong>-0.97%</strong>，公司可能在為股東提供滿意回報方面面臨挑戰。</p>
</div><p><strong>Return on Assets (ROA):</strong> Hinge Health's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>-0.25%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<div class="lb-trans"><p><strong>資產回報率（ROA）：</strong> Hinge Health 的 ROA 低於行業標準，表明在有效利用資產方面存在困難。ROA 為 <strong>-0.25%</strong>，公司可能在從其資產中提供滿意回報方面面臨挑戰。</p>
</div><p><strong>Debt Management:</strong> Hinge Health's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.04</strong>.</p>
<div class="lb-trans"><p><strong>債務管理：</strong> Hinge Health 的債務與股本比率低於行業規範，表明其財務結構良好，比例為 <strong>0.04</strong>。</p>
</div><h2>What Are Analyst Ratings?</h2>
<div class="lb-trans"><h2>什麼是分析師評級？</h2>
</div><p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.</p>
<div class="lb-trans"><p>分析師是銀行和金融系統中的專家，通常為特定股票或特定行業報告。這些人研究公司財務報表，參加電話會議和會議，並與相關內部人士交談，以確定股票的分析師評級。通常，分析師每季度會對每隻股票進行評級。</p>
</div><p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<div class="lb-trans"><p>除了他們的評估外，一些分析師還通過提供關鍵指標的預測（如收益、收入和增長估計）來擴展他們的見解。這些補充信息為交易者提供了進一步的指導。必須認識到，儘管他們是專家，分析師也是人，只能根據他們的信念提供預測。</p>
</div><p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>
<div class="lb-trans"><p>本文由 Benzinga 的自動內容引擎生成，並由編輯審核。</p>
</div>

分析師對 Hinge Health 未來發展的預期